Cargando…
Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro
Pralatrexate (Folotyn; PLX) and belinostat (Beleodaq; BLS) are registered for the treatment of patients with peripheral T-cell lymphoma (PTCL) and are being considered for other lymphomas. In this study we investigated whether BLS had the ability to potentiate the cytotoxicity of PLX. A panel of lym...
Autores principales: | Peters, Godefridus J., van Gemert, Frank P. A., Kathmann, Ietje, Reddy, Guru, Cillessen, Saskia A. G. M., Jansen, Gerrit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581941/ https://www.ncbi.nlm.nih.gov/pubmed/33163492 http://dx.doi.org/10.3389/fcell.2020.577215 |
Ejemplares similares
-
Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat
por: Chang, Chi-Ming, et al.
Publicado: (2023) -
Computational Development of Inhibitors of Plasmid-Borne Bacterial Dihydrofolate Reductase
por: Silva, Pedro J.
Publicado: (2022) -
The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
por: Buckley, Michael T, et al.
Publicado: (2007) -
Optimized peptide based inhibitors targeting the dihydrofolate reductase pathway in cancer
por: Singh, Amrinder, et al.
Publicado: (2018) -
Dihydrofolate Reductase Inhibitors: The Pharmacophore as a Guide for Co-Crystal Screening
por: Baptista, João A., et al.
Publicado: (2021)